Top Stories
Aspen is moving a Parkinson's disease cell therapy into Phase III testing, while Bambusa is advancing a portfolio of bispecific antibodies for inflammatory conditions.
The oral ileal bile acid transporter inhibitor significantly improved cholestatic pruritus compared with placebo.
BMS gained the alpha-emitting therapy RYZ101 through the $4.1-billion purchase of RayzeBio.
Thomas Appio, who is CEO of Bausch Health, will lead the firm on an interim basis.
The treatment's 17.05-metre improvement on the six-minute walk test distance over placebo in adolescents and adults was deemed statistically non–significant.
Conference News
Phase 1b study in atopic dermatitis demonstrated a statistically significant mean reduction of 2.1 years in measured skin epigenetic age after four weeks of treatment with RLS-1496 (p=0.032), with red...
ATHENS, Ga. and SAN JOSE, Calif., Oct. 12, 2026 /PRNewswire/ -- Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines tha...
New prespecified analyses showed consistent findings across clinically important and difficult to treat subgroups, including patients with prior biologic exposureFindings build on first positive resul...
New long-term data showed clinical remission rates of up to 94% and endoscopic remission rates of up to 61% in adults with moderately to severely active Crohn's disease88% of patients achieved 90-day ...
Oral presentation at the Breakthrough T1D Clinical & Research Congress highlights preclinical studies showing reduced blood glucose levels, delayed disease onset, and improved survival in a Type 1 dia...
